iRadimed (NASDAQ:IRMD) Issues Q2 2026 Earnings Guidance

Key Points

• iRadimed issued Q2 2026 guidance of EPS $0.44–$0.48 (consensus $0.46) and revenue $20.0M–$21.0M (consensus $21.1M), and updated FY 2026 EPS guidance to $2.06–$2.21.
• The company raised its quarterly dividend to $0.20 (from $0.17), implying an annualized $0.80 payout, a ~1.0% yield and a payout ratio around 45.7%.
• Analysts hold a mostly "Buy" consensus with an average price target of $120, while the stock recently traded near $83.44 (market cap ≈ $1.07B), leaving a notable gap to analyst targets.

iRadimed (NASDAQ:IRMD - Get Free Report) issued an update on its second quarter 2026 earnings guidance on Friday morning. The company provided EPS guidance of 0.440-0.480 for the period, compared to the consensus EPS estimate of 0.460. The company issued revenue guidance of $20.0 million-$21.0 million, compared to the consensus revenue estimate of $21.1 million. iRadimed also updated its FY 2026 guidance to 2.060-2.210 EPS.

iRadimed Stock Down 0.3%

Shares of NASDAQ IRMD opened at $83.44 on Friday. The firm's 50-day moving average price is $96.69 and its two-hundred day moving average price is $93.87. iRadimed has a 52-week low of $50.31 and a 52-week high of $107.90. The stock has a market capitalization of $1.07 billion, a P/E ratio of 47.68 and a beta of 1.11.

iRadimed (NASDAQ:IRMD - Get Free Report) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. The firm had revenue of $22.69 million for the quarter, compared to analysts' expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, equities research analysts expect that iRadimed will post 1.94 earnings per share for the current year.

iRadimed Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were issued a $0.20 dividend. This is an increase from iRadimed's previous quarterly dividend of $0.17. This represents a $0.80 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend was Monday, February 23rd. iRadimed's dividend payout ratio is 45.71%.

Analyst Ratings Changes

IRMD has been the topic of a number of recent research reports. Lake Street Capital reissued a "buy" rating and issued a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. Freedom Capital raised shares of iRadimed to a "strong-buy" rating in a report on Thursday, April 2nd. Finally, Roth Mkm reissued a "buy" rating and issued a $120.00 target price on shares of iRadimed in a report on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $120.00.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 3,750 shares of iRadimed stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $89.16, for a total transaction of $334,350.00. Following the sale, the chief executive officer owned 2,198,750 shares of the company's stock, valued at approximately $196,040,550. The trade was a 0.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 48,750 shares of company stock worth $4,708,950 over the last quarter. Insiders own 36.80% of the company's stock.

Institutional Investors Weigh In On iRadimed

A number of hedge funds have recently made changes to their positions in IRMD. Quarry LP bought a new stake in shares of iRadimed during the third quarter valued at approximately $40,000. Tower Research Capital LLC TRC raised its holdings in shares of iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 495 shares during the last quarter. Virtus Advisers LLC bought a new stake in shares of iRadimed during the third quarter valued at approximately $117,000. Aquatic Capital Management LLC raised its holdings in shares of iRadimed by 210,400.0% during the third quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider's stock valued at $150,000 after buying an additional 2,104 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of iRadimed during the third quarter valued at approximately $164,000. Institutional investors own 92.34% of the company's stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.